Ftse Mib
36.106,24
-0,44%
DAX
20.899,48
0,01%
S&P 500
5.996,66
1,00%
NASDAQ
19.630,20
1,51%
Bitcoin
107.098,00
3,86%
Pepperstone
Advertisement
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Biotech Acquisition Company (BIOT) Biotech Acquisition Company (BIOT) Notizie

BIOT

Biotech Acquisition (BIOT)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIOT
DataOraFonteTitoloSimboloCompagnia
14/02/202323:02Edgar (US Regulatory)Termination of Registration of a Class of Security Under Section 12(g) (15-12g)NASDAQ:BIOTBiotech Acquisition Company
13/02/202320:12Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BIOTBiotech Acquisition Company
02/02/202322:56Edgar (US Regulatory)Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)NASDAQ:BIOTBiotech Acquisition Company
02/02/202312:04Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BIOTBiotech Acquisition Company
27/01/202319:19Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:BIOTBiotech Acquisition Company
04/01/202323:51PR Newswire (US)Biotech Acquisition Company Announces Plan for New Sponsor to Make Additional Contributions to Trust Account Upon Approval of Proposed Extension AmendmentNASDAQ:BIOTBiotech Acquisition Company
04/01/202321:20Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BIOTBiotech Acquisition Company
22/11/202212:05Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BIOTBiotech Acquisition Company
14/11/202219:44Edgar (US Regulatory)Notification That Quarterly Report Will Be Submitted Late (nt 10-q)NASDAQ:BIOTBiotech Acquisition Company
01/08/202214:00Business WireBlade Therapeutics to Participate in “Drug Development in Pulmonary Medicine” Panel Discussion at 2022 BTIG Biotechnology ConferenceNASDAQ:BIOTBiotech Acquisition Company
17/06/202222:06Edgar (US Regulatory)Withdrawal of Registration Statement (rw)NASDAQ:BIOTBiotech Acquisition Company
13/06/202214:06PR Newswire (US)Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination AgreementNASDAQ:BIOTBiotech Acquisition Company
03/06/202212:03Edgar (US Regulatory)Filing of Certain Prospectuses and Communications in Connection With Business Combination Transactions (425)NASDAQ:BIOTBiotech Acquisition Company
03/06/202202:58PR Newswire (US)Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business CombinationNASDAQ:BIOTBiotech Acquisition Company
24/05/202215:13PR Newswire (US)Biotech Acquisition Company Announces Submission of Prospectus Supplement to the Proxy Statement/Prospectus to The Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.NASDAQ:BIOTBiotech Acquisition Company
18/05/202215:01Business WireBlade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International ConferenceNASDAQ:BIOTBiotech Acquisition Company
16/05/202215:01Business WireBlade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International ConferenceNASDAQ:BIOTBiotech Acquisition Company
10/05/202212:08Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BIOTBiotech Acquisition Company
10/05/202200:10PR Newswire (US)Biotech Acquisition Company and Blade Therapeutics, Inc. Announce Effectiveness of Registration Statement on Form S-4, Date of BAC's Extraordinary General Meeting to Approve Proposed Business Combination and Signing of Up to $75 million Committed Equity FaNASDAQ:BIOTBiotech Acquisition Company
09/05/202223:26Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NASDAQ:BIOTBiotech Acquisition Company
18/04/202212:05Edgar (US Regulatory)Registration Statement for Securities to Be Issued in Business Combination Transactions (s-4/a)NASDAQ:BIOTBiotech Acquisition Company
04/04/202221:49PR Newswire (US)Biotech Acquisition Company Announces Filing of First Amendment to Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.NASDAQ:BIOTBiotech Acquisition Company
04/04/202214:00Business WireBlade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data PackageNASDAQ:BIOTBiotech Acquisition Company
24/03/202213:00Business WireBlade Therapeutics to Present Data from Preclinical and Phase 1 Studies of Cudetaxestat at the American Thoracic Society 2022 International ConferenceNASDAQ:BIOTBiotech Acquisition Company
16/03/202213:00PR Newswire (US)Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc.NASDAQ:BIOTBiotech Acquisition Company
15/03/202221:44Edgar (US Regulatory)Securities Registration: Business Combination (s-4)NASDAQ:BIOTBiotech Acquisition Company
08/03/202212:04Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BIOTBiotech Acquisition Company
08/03/202212:01Edgar (US Regulatory)Amended Current Report Filing (8-k/a)NASDAQ:BIOTBiotech Acquisition Company
07/03/202214:00Business WireBlade Therapeutics to Participate in Upcoming Investor ConferencesNASDAQ:BIOTBiotech Acquisition Company
12/01/202214:00Business WireBlade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary FibrosisNASDAQ:BIOTBiotech Acquisition Company
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BIOT

La tua Cronologia

USOTC
ILIM
IL2M (PK)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network